Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an
experimental drug that blocks Hsp90. It is being evaluated for safety in patients with
cancer.